Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
Axitinib can can inhibit the activity of multiple angiogenesis-related signaling pathways.
Promising anti-tumor activity has been demonstrated in patients with renal cell carcinoma,
thyroid cancer, and melanoma. The potent anti-angiogenic activity of axitinib makes it a
promising agent for the treatment of HCC.
This is a single-arm, open-label phase II trial. Eligible patients will receive axitinib,
starting at 5 mg orally twice daily in the fasting status, until objective disease
progression, development of unacceptable toxicity, or voluntary discontinuation. Dose
titration will be done according to the severity of adverse events.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
8 weeks until tumor progression
Ann-Lii Cheng, MD, PhD
United States: Food and Drug Administration